Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial

Nicole J Kellow1*, Melinda T Coughlan2,3, Gayle S Savige1 and Christopher M Reid1

Abstract

Background: Advanced glycation endproducts (AGEs) contribute to the development of vascular complications of diabetes and have been recently implicated in the pathogenesis of diabetes. Since AGEs are generated within foodstuffs upon food processing, it is increasingly recognised that the modern diet is replete with AGEs. AGEs are thought to stimulate chronic low-grade inflammation and promote oxidative stress and have been linked to the development of insulin resistance. Simple therapeutic strategies targeted at attenuating the progression of chronic low-grade inflammation and insulin resistance are urgently required to prevent or slow the development of type 2 diabetes in susceptible individuals. Dietary modulation of the human colonic microbiota has been shown to confer a number of health benefits to the host, but its effect on advanced glycation is unknown. The aim of this article is to describe the methodology of a double-blind placebo-controlled randomised crossover trial designed to determine the effect of 12 week consumption of a prebiotic dietary supplement on the advanced glycation pathway, insulin sensitivity and chronic low-grade inflammation in adults with pre-diabetes.

Methods/Design: Thirty adults with pre-diabetes (Impaired Glucose Tolerance or Impaired Fasting Glucose) aged between 40–60 years will be randomly assigned to receive either 10 grams of prebiotic (inulin/oligofructose) daily or 10 grams placebo (maltodextrin) daily for 12 weeks. After a 2-week washout period, study subjects will crossover to receive the alternative dietary treatment for 12 weeks. The primary outcome is the difference in markers of the advanced glycation pathway carboxymethyllysine (CML) and methylglyoxal (MG) between experimental and control treatments. Secondary outcomes include HbA1c, insulin sensitivity, lipid levels, blood pressure, serum glutathione, adiponectin, IL-6, E-selectin, myeloperoxidase, C-reactive protein, Toll-like Receptor 4 (TLR4), soluble receptor for AGE (sRAGE), urinary 8-isoprostanes, faecal bacterial composition and short chain fatty acid profile. Anthropometric measures including BMI and waist circumference will be collected in addition to comprehensive dietary and lifestyle data.

Discussion: Prebiotics which selectively stimulate the growth of beneficial bacteria in the human colon might offer protection against AGE-related pathology in people at risk of developing type 2 diabetes.

(Continued on next page)
Background

Advanced Glycation Endproducts (AGEs) are formed via the Maillard reaction, which consists of a complex network of non-enzymatic reactions involving the carbonyl groups of reducing sugars which react with the amino groups of proteins [1]. AGEs are generated in vivo as a normal consequence of metabolism, but their formation is accelerated under conditions where blood glucose is chronically elevated such as poorly controlled diabetes [2]. AGE formation is also increased in the presence of oxidative stress, which is frequently observed in individuals with the metabolic syndrome [3,4]. Overproduction of reactive oxygen species (ROS) can result in maladaptive responses including interruption of cellular glycolysis, which can generate highly reactive dicarbonyl compounds capable of rapid AGE formation [5].

Excessive AGE accumulation can lead to several pathophysiological consequences. AGE-modification of proteins results in changes in structure and/or function. For example, the AGE-modification of extracellular collagen reduces its elasticity and solubility, and results in increased stiffness, disturbed cellular adhesion and reduced turnover contributing to basement membrane thickening [6]. Intracellularly, AGE-modification of mitochondrial proteins is associated with suppression in the activity of respiratory chain enzymes and overproduction of ROS [7,8]. Indeed, glycated proteins provide stable active sites for catalysing the formation of free radicals [9]. Finally, AGEs are able to bind and activate a range of receptors, which then trigger a downstream cascade of pathogenic mediators. Interaction of AGEs with the Receptor for AGEs (RAGE) promotes activation of the transcription factor nuclear factor kappa-B (NF-κB), with subsequent upregulation of chemokines, such as MCP-1 and pro-inflammatory mediators such as TGFβ in addition to pro-inflammatory cytokines which are known to be involved in thrombogenesis, vascular inflammation and pathological angiogenesis. These RAGE-mediated events contribute to many of the long-term complications of diabetes [10]. AGE/RAGE ligation also promotes overproduction of ROS which can then activate NF-κB [11], a key driver of inflammation.

More recently, AGEs have been implicated in the pathogenesis of both type 1 and type 2 diabetes. Several studies have shown that AGEs are associated with insulin resistance [12,13], and can induce low-grade inflammation [14] and pancreatic beta cell dysfunction [15,16].

In contrast to endogenous AGE formation, AGEs are also absorbed by the body from exogenous sources such as cigarette smoke and through consumption of processed foods [17]. Since AGEs are generated within foodstuffs upon heating and food processing, it is increasingly recognised that the modern diet is replete with AGEs [18]. AGE-restricted diets can arrest the development of type 2 diabetes in animal models [19]. A recent study found that excess consumption of AGE-precursors in mice over several generations led to the development of insulin resistance [20]. Human trials have found that dietary AGE restriction can improve insulin sensitivity [21,22] and decrease markers of oxidative stress [23] or inflammation [24]. Further studies are required to confirm the long-term benefits of dietary AGE-restriction in humans [25]. However, simple, safe and effective interventions which prevent or minimise excessive AGE accumulation and subsequent AGE-related pathology in people with diabetes and/or in those at risk of developing the condition are warranted.

Interventions which influence the human intestinal microbiota are worthy of further investigation given that specific micro-organisms have the ability to significantly affect host metabolism. Gut bacteria play an important role in the host immune system, modulation of inflammatory processes, extraction of energy from the host’s diet, fermentation of dietary fibres to produce short-chain fatty acids, alteration of human gene expression, regulation of intestinal permeability, production of some vitamins and promotion of mineral absorption by the host [26-31]. Furthermore, the total quantity and relative proportions of distinct bacterial species found in the colon differ between lean and obese individuals as well as between individuals with and without diabetes [32,33].

It is thought that certain dietary AGEs are largely undigested by human gut enzymes and eventually enter the colon, where they may act as a growth substrate for detrimental bacteria such as some Clostridium and Bacteroides species [34]. Therefore it is conceivable that individuals who consume highly processed diets (which contain large quantities of AGEs) may adversely alter their colonic microbial composition, potentially enhancing their risk for the development of metabolic diseases such as obesity and type 2 diabetes [35].

Therapeutic manipulation of the gut microbiota and restoration of normobiosis could potentially reduce circulating AGE levels and improve the metabolic health.
of individuals at risk for the development of type 2 diabetes. Regular consumption of prebiotics to promote the growth of beneficial gut bacterial flora is one such avenue currently under investigation. Prebiotics are non-digestable plant-derived carbohydrates which confer health benefits to the host by acting as a fermentation substrate in the colon, stimulating the preferential growth and activity of a limited number of beneficial microbial species [36]. Supplementation of the human diet with prebiotic fructans such as inulin or fructo-oligosaccharides alters the bacterial composition of the large intestine by favouring the selective proliferation of beneficial lactic acid-producing species such as bifidobacteria and lactobacilli. Prebiotic-stimulated increases in intestinal Bifidobacterium species have been shown to attenuate the production of ROS and markers of inflammation in individuals consuming high fat diets [37].

While the complex interactions between diet, intestinal microbiota and host metabolism are still being elucidated, no studies have investigated the effect of dietary prebiotics on circulating AGE concentrations. This trial was designed to investigate the effect of a prebiotic dietary supplement on AGE accumulation and explore changes to the growth and activity of specific gut microbiota in adults diagnosed with prediabetes.

Methods/Design
Study design and setting

This is a 6.5-month randomised crossover controlled clinical trial (RCT) in which adults aged 40–60 years with diagnosed pre-diabetes will be enrolled. Potential study participants will be identified from General Practice (GP) clinics throughout South Gippsland, Victoria. The study design is presented in Figure 1.

Inclusion criteria

Individuals aged between 40–60 years and diagnosed with prediabetes (Impaired Fasting Glucose or Impaired Glucose Tolerance) within the previous 12 months. Diagnosis will have been made at each individual’s local GP clinic after undertaking an Oral Glucose Tolerance Test (OGTT). Prediabetes was defined as a fasting plasma glucose concentration ≥ 6.1 and < 7.0 mmol/L followed by a 2-hour post glucose load glucose concentration < 7.8 mmol/L, or a fasting plasma glucose < 7.0 mmol/L followed by a 2-hour post glucose load glucose concentration ≥ 7.8 and < 11.1 mmol/L [38].

Exclusion criteria

Individuals previously diagnosed with type 1, type 2 diabetes or impaired renal function (eGFR < 90 mL/min/1.73 m²), individuals with known gastrointestinal pathology (coeliac disease, inflammatory bowel disease), pregnant women, smokers, individuals who have taken antibiotics, dietary prebiotic or probiotic nutritional supplements within the previous three months, individuals taking aspirin or Vitamin B, individuals who have made major dietary or lifestyle changes in the previous three months, individuals who are unwilling to provide blood, urine and stool samples or are unable to attend their local pathology collection centre.

Ethics

The trial has received ethical approval from the Monash University Human Research Ethics Committee.

Sample size calculation

The minimum difference we wish to detect is 0.4 micromol/L serum CML (20% reduction in CML), with a standard deviation of 0.4 [39] with 5% Significance and 80% Power. This calculates as a total sample size of 18 individuals, plus 12 individuals to allow for withdrawals = 30 subjects required. Epidemiological studies have demonstrated a positive correlation between serum CML and all-cause and cardiovascular mortality, cardiovascular disease, glucose intolerance, impaired insulin secretion, renal impairment and diabetic vascular complications [40,41]. A 0.4 micromol/L increase in serum CML concentration represented a 68% increased risk for all-cause mortality over seven years in a large prospective cohort study [42].

Baseline assessment

The study timeline is presented in Figure 2. Following recruitment and screening, consenting participants will undergo a baseline assessment at their local GP clinic. The baseline assessment will be undertaken by the research dietitian, who will collect demographic details, medical and social history (living situation, marital status, current occupation), physical activity questionnaire, dietary intake assessment, anthropometric measurements including Body Mass Index (BMI) and waist circumference. Participants will also be instructed to attend the local pathology centre to provide a stool sample, 24-hour urine collection, and have blood taken for analysis.

Randomisation

Randomisation of participants to intervention/placebo sequence will be completed by a local pharmacist using a permuted-block randomisation stratified by gender via the web site www.randomization.com. The pharmacist will distribute the experimental and placebo nutritional supplements to participants in the appropriate sequence. Other than provision of supplements, the pharmacist will have no contact with study participants or involvement in data collection or analysis. Dietary supplements will be provided in sealed opaque packages which will be weighed at the conclusion of the study in order to assess compliance. The supplements will be packaged
Figure 1 Trial protocol.

- **Recruitment**
- **Randomisation**
- **Baseline data collection**
- **Intervention**: 12 weeks
- **Washout**: 2 weeks
- **Crossover to alternate treatment**
- **Intervention**: 12 weeks
- **Analysis**

Fig. 2 Study flowchart.

| Day 0 | Day 1-90 | Day 91-104 | Day 105-195 |
|-------|----------|------------|-------------|
| Screening, consent and randomisation | Dose escalation | intervention 1 | Intervention 2 |
| (Group A) | Inulin (Group A) | OR | Placebo (Group B) |
| OR | Placebo (Group B) | Washout | Placebo (Group B) |
| (2 weeks) | 2 weeks | OR | Placebo (Group A) |

- Baseline data collection: demographics, medical and social history, anthropometry, diet history, physical activity, collection of blood, urine and stool samples
- Post-intervention data collection: anthropometry, diet history, physical activity, GIT symptom VAS, collection of blood, urine and stool samples
off-site by an external pharmaceutical packaging agency. Each package will contain a participant’s study identification number and will be labelled as either Supplement 1 or Supplement 2 corresponding to the first and second intervention periods. This will ensure all investigators and participants are blinded to the treatment. Blinding will cease only after statistical analysis of the data has been completed.

**Intervention**
Participants will be randomly assigned to receive either 10 g of chicory-derived inulin/oligofructose powder (kindly provided by Beneo-Orafti Active Food Ingredients, Belgium) (intervention) or 10 g of maltodextrin powder (placebo) daily. Previous studies have demonstrated the bifidogenic effect of daily consumption of 5 g and 8 g dietary inulin supplements [43]. The inulin and maltodextrin powders to be consumed are both tasteless and can be mixed into hot or cold liquids or semi-solid foods. Participants will be instructed how to incorporate their supplement into their usual diet, and advised to gradually increase their dose over ten successive days until the target dose is reached. This stepped escalation in supplement dose aims to minimise gastrointestinal discomfort for participants, as a sudden increase in dietary prebiotic intake may result in increased stool frequency, abdominal bloating and flatulence until the bowel adapts to the increased fibre intake [44]. Written instructions will also be provided. Participants will be advised to consume each dietary supplement daily for 90 days, and otherwise maintain their usual dietary intake and level of physical activity. Gastrointestinal tolerance to the dietary supplements will be indicated by each study participant using a visual analogue scale as described below.

**Follow up visits**
Visits to the GP clinic will be scheduled for each participant at the conclusion of both Intervention 1 and Intervention 2 treatment periods, in order to provide follow-up data. Information collected will include anthropometric measurements, dietary intake assessment and physical activity assessment. Each participant will complete a self-administered questionnaire designed to assess gastrointestinal tolerance to the dietary supplement. Completed questionnaires will be placed into sealed opaque envelopes in order to maintain blinding of the researcher collecting data during the follow-up visits. Participants will also be instructed to attend the local pathology centre to provide urine and stool samples, and have blood taken for analysis.

**Safety considerations**
All adverse events will be documented.

**Outcome measurements**
The primary outcome of interest is the difference in serum AGE and AGE-precursor concentration (measured as CML and MG respectively) between experimental and control treatments. Secondary outcomes include HbA1c, insulin resistance (measured indirectly by homeostasis model assessment), antioxidant capacity (reduced glutathione), markers of oxidative stress on lipid molecules (urinary isoprostanes), inflammatory biomarkers (serum IL-6, high sensitivity C-reactive protein, MCP-1, sRAGE), adhesion molecules (E-selectin), gut barrier integrity (TLR4), 24-hour urine and faecal CML and MG concentrations, faecal bacterial composition (Bifidobacterium spp., Lactobacillus spp., Roseburia spp., Faecalibacterium prausnitzii and Akkermansia muciniphila) and faecal short chain fatty acid concentrations. Lipid levels (serum total cholesterol, LDL, HDL, TG) and blood pressure will also be measured. Anthropometric measurements including BMI and waist circumference will be collected, in addition to comprehensive dietary and lifestyle data. Gastrointestinal side-effects will be assessed using a visual analogue scale adapted from Lecerf et al. [45]. The scale rates nine items including flatulence, bloating, rumbling, abdominal cramps, a global digestive tolerance score calculated from the five previous items, stool consistency, stool frequency and general well-being through disturbances in usual and professional activities as well as disturbances in personal and social activities. Items are scored on a 10 cm linear scale.

**Data collection**

**Dietary intake**
An experienced research dietitian will obtain a comprehensive dietary history from each study participant at baseline and at the completion of each intervention period. A dietary history is a structured interview method consisting of questions regarding habitual food intake. It involves a 24-hour diet recall followed by a food frequency questionnaire to clarify information about usual consumption over the previous month. Usual portion sizes will be obtained in household measures and with the use of photographic aids. The dietitian will review the dietary history with each participant, probing for details on portion sizes and cooking methods in order to improve data accuracy. Dietary AGE content will be estimated from an open source database which lists the AGE concentration of foods using validated analytical techniques [46]. Dietary macro and micronutrient intakes will be estimated using the Foodworks nutrient software program (Xyris Software, NSW, Australia). Each participant will also be randomly contacted by telephone during the study and asked to provide a 24-hour diet recall, and changes in urinary urea excretion will be monitored in order to validate the dietary history data collected [47].
Physical activity will be estimated by asking participants to complete the International Physical Activity Questionnaire (Short Form) prior to and at the completion of experimental and placebo intervention periods [48].

**Anthropometry**

Body weight will be measured in participants wearing light clothes without shoes using a digital scale (Seca, Germany) to the nearest 0.1 kg. Height will be measured using a portable stadiometer (Seca, Germany) to the nearest 0.1 cm. BMI is calculated by dividing weight (kg) per height (m) square. Waist circumference will be measured at the midpoint of the lowest rib and iliac crest using a measuring tape to the nearest 0.1 cm. Body composition (total body water, fat mass, fat-free mass) will be determined using Bioelectrical Impedance Analysis (BodyStat-1500, Bodystat, Douglas, Isle of Man, United Kingdom). Ambulatory blood pressure will be measured using an electronic blood pressure machine (Omron Corporation, Kyoto, Japan), with subjects at rest in a seated position. All anthropometric measurements will be conducted in duplicate, with the mean measurement recorded.

**Laboratory investigations**

Biological samples will be collected at baseline and at completion of each three-month supplement intervention period and stored at −80°C immediately after collection. Twenty ml of fasting venous blood will be collected from each participant by phlebotomy into a sodium fluoride EDTA tube, a heparin-lined vacuum collection. Twenty ml of fasting venous blood will be centrifuged at 5000 × g for 15 minutes at room temperature. Supernatants will be decanted and frozen overnight. The following day, samples will be thawed and the pH of each sample adjusted to 6.5 using 4 N KOH. Oxalic acid will be added at a final concentration of 0.03% and SCFA concentrations determined by gas chromatography with use of a Hewlett-Packard 5880A gas chromatograph (Hewlett Packard, Palo Alto, CA, USA) containing an 80/120 Carboxypack B column (Supelco Inc., Bellefonte, PA, USA) and the pH of each sample adjusted to 6.5 using 4 N KOH. Oxalic acid will be added at a final concentration of 0.03% and SCFA concentrations determined by gas chromatography with use of a Hewlett-Packard 5880A gas chromatograph (Hewlett Packard, Palo Alto, CA, USA) containing an 80/120 Carboxypack B column (Supelco Inc., Bellefonte, PA, USA). Data will be expressed as log CFU/g of faeces.
Statistical analysis
Outcome analyses will be undertaken on an intention-to-treat basis. Data will be presented as means ± SD. The Kolmogorov-Smirnov goodness-of-fit test will be used to test for normal distribution, and data not normally distributed will be log-transformed. Correlation analyses will be performed using the Pearson correlation coefficient. Significance of changes during the study will be assessed by comparing change of means between placebo and prebiotic treatment periods by paired sample t-tests. Trial data will be analysed using a linear mixed model design based on repeated measures to account for fixed factors such as treatment sequence (inulin – placebo vs placebo - inulin) and treatment period (intervention 1 vs intervention 2) in addition to participants as a random factor. Significant differences will be defined as a value of P < 0.05 based on two-sided tests. Any differences in physical activity levels, anthropometry, energy or nutrient intake during the course of the trial will be identified using ANOVA. Gastrointestinal symptom data obtained by visual analogue scale will be analysed using the Wilcoxon signed rank test. Effect sizes including 95% confidence intervals will be calculated for all significant outcomes. Data analysis will be performed using SPSS 20.0 software (SPSS, Chicago, IL).

Discussion
AGEs are derived from both exogenous and endogenous sources, and the rate at which AGEs accumulate in the body is dependent to a large extent on the chronological age, lifestyle and metabolic health of an individual. Smoking cigarettes and consuming foods containing high concentrations of AGEs (and their precursors) increases the accumulation, but adherence to such diets can be challenging given that foods high in AGEs are very palatable due to their enhanced flavour, colour and aroma [60].

Supplementation of the diet with bifidogenic prebiotic fibres (such as inulin) may reduce or retard the accumulation of AGEs in individuals at risk of developing type 2 diabetes. Prebiotics have been shown to improve and restore optimal microbial balance within the gastrointestinal tract, potentially reducing AGE absorption and/or production by the human host. Preliminary investigations indicate that consuming a high-AGE diet is sufficient to favour the proliferation of potentially pathogenic colonic bacteria over more beneficial species. Consumption of glycated proteins [34], fried meats [61] and toasted wheat flakes [62] encouraged the preferential growth of greater numbers of detrimental gram negative and sulphate-reducing colonic micro-organisms when compared to control diets. Short Chain Fatty Acids (SCFAs) produced as a bacterial by-product of prebiotic fermentation act to lower the intestinal pH, inhibiting the growth of protein-degrading micro-organisms capable of producing potentially toxic metabolites. SCFAs also stimulate colonic smooth muscle contractions, speeding intestinal transit and limiting the time available for protein fermentation and putrefaction to occur in the gut [63]. Therapeutic manipulation of the gut microbiota with prebiotics may restore gut normobiosis and reduce AGE accumulation in humans at risk for type 2 diabetes development by the following mechanisms:

Maintenance of gut barrier function
Kinetic studies have estimated that up to 30% of dietary AGEs consumed are intestinally absorbed [64]. Under circumstances of increased intestinal permeability, it is likely that greater quantities of dietary AGEs and their reactive dicarbonyl precursors may be able to gain entry into the systemic circulation. Elevated levels of circulating proinflammatory cytokines and ROS frequently observed in individuals with prediabetes are known to compromise tight junctions between cells, disrupting the integrity of the intestinal barrier and enabling the absorption of larger, potentially deleterious compounds [65]. Prebiotic fermentation products may reduce gastrointestinal permeability and as a result limit the absorption of exogenous AGEs.

The SCFAs acetate and butyrate are intricately involved in the maintenance of gut epithelial integrity. Acetate increases colonic blood flow and butyrate is the principal fuel for colonocytes, assisting to optimise epithelial cell health [66]. Butyrate reduces gastrointestinal permeability by enhancing the activation of the peroxisomal proliferator-activated receptor gamma (PPARgamma) gene, a nuclear receptor involved in the attenuation of inflammation in colonic epithelial cells [67]. Butyrate also upregulates the expression of mucin-associated genes important in maintaining the integrity of the intestinal mucosal barrier [68]. Oligofructose supplementation in mice has been shown to increase the expression of zonula and occludin, proteins important in the maintenance of tight junctions between gastrointestinal cells [69], and a dietary inulin intervention reduced markers of intestinal permeability in healthy adult males [70]. Butyrate is a histone deacetylase inhibitor and is likely to promote the transcription of these tight junction
proteins. Prebiotic-induced changes in gut microbiota also increase endogenous production of Glucagon-like peptide 2 (GLP-2), which enhances gut barrier function by promoting the proliferation of crypt cells [71,72].

Reduction of oxidative stress, inflammation and insulin resistance

Increased production of ROS stimulate endogenous AGE formation by oxidising glucose and unsaturated fatty acids to generate reactive dicarbonyls. Experimental drug treatments which attenuate oxidative stress have previously demonstrated reductions in serum AGE levels [73]. Cytokine production at sites of inflammation stimulate immune cell activation of NADPH oxidase (NOX) and production of myeloperoxidase, enzymes involved in the oxidation of amino acids to form AGE precursors [74]. Activated immune cells can also secrete the high-mobility group box 1 (HMGB-1) protein which is capable of binding to RAGE, thereby inducing further inflammation [75].

A high fat diet (independent of the level of obesity in the host) is associated with negative changes in bacterial communities within the colon [76]. In response to a high fat meal, bacterial lipopolysaccharide (LPS) translocates from the intestine into the host circulation, resulting in ‘metabolic endotoxia’ [77,78]. LPS is a major component of the outer membrane of gram negative bacteria, and is a potent activator of the mammalian immune system. LPS interaction with immune cells stimulates macrophage over-production of ROS, enhances the secretion of pro-inflammatory cytokines, and contributes to weight gain and development of insulin resistance [79,80]. Individuals with type 2 diabetes have been found to possess endotoxemia levels 2-fold higher than people without diabetes [81]. Metabolic endotoxemia also positively correlates with total energy intake and fasting insulin levels in the general population [82]. In mice with high fat diet-induced metabolic endotoxemia, nutritional supplementation of the diet with prebiotics restored intestinal levels of gram positive bacteria (particularly Bifidobacterium species) and subsequently improved glucose tolerance and reduced circulating concentrations of LPS and pro-inflammatory cytokines [83]. Human trials involving dietary prebiotic supplementation have successfully reduced serum LPS levels [45] and markers of lipid peroxidation (a process which generates AGE precursors), possibly through the reduction of ROS production or the direct antioxidant ability of some Bifidobacterium and Lactobacillus bacterial species [84,85].

SCFAs produced as a bacterial by-product of prebiotic fermentation are absorbed into the host circulation, effecting the expression of a wide range of genes in distal tissues associated with cell proliferation, differentiation and apoptosis. SCFAs are ligands for the G-protein coupled receptors (GPRs) GPR41 and GPR43 [86] on immune cells. These receptors are involved in down-regulating inappropriate immune cell production of pro-inflammatory cytokines, chemokines and ROS [87]. The SCFAs acetate, propionate and butyrate exhibit a variety of anti-inflammatory actions through inhibition of NFκB activation, prevention of LPS-stimulated TNFα production in neutrophils and suppression of cytokine production [31,88-90].

Numerous other immune modulating effects have been observed secondary to gut bacterial activity including the production of anti-inflammatory compounds such as polysaccharide A [91], peptidoglycan [92] and conjugated linoleic acid [93], and the induction of T-regulatory cells [26].

Promotion of weight reduction

An energy-restricted diet resulting in weight loss has been shown to reduce serum AGE levels in overweight and obese individuals [94]. The consumption of prebiotics in human clinical trials has promoted self-reported satiety [95], weight reduction, reduced production of the orexigenic hormone grehlin and stimulated expression of the appetite-reducing hormone peptide YY (PYY) [96]. Interaction with GPR41 by the SCFAs propionate and butyrate increases satiety [97], upregulates PYY production and modulates the expression of leptin, a hormone important in controlling energy intake and expenditure [31]. In mice, the selective growth of certain lactobacillus species in the colon reduced body fat storage through the up-regulation of fiaf (fasting induced adipose factor) gene expression and inhibition of lipoprotein lipase (LPL) [98-100]. These findings may have the potential to affect weight reduction in humans and subsequently reduce circulating AGE levels.

Enhanced antioxidant capacity

Inulin enhances the proliferation of lactic acid producing bacteria capable of synthesising B-group vitamins, some of which have an antioxidant capacity [101]. These vitamins can be utilised by the human host to neutralise ROS. Vitamins B1 and B6 trap the carbonyl groups of highly reactive AGE precursors before they can react with proteins [102]. Some Lactobacillus and Bifidobacterium species are efficient scavengers of the lipid peroxidation product malondialdehyde, protecting the host from excessive accumulation of this toxic AGE precursor [84]. Inulin also exhibits antioxidant properties independent of altering gut bacterial growth and is able to scavenge a number of ROS, which may help to reduce lipid peroxidation in the stomach [103].

The SCFA butyrate, produced as a bacterial by-product of inulin fermentation, has been shown to increase colonic glutathione production [104]. Glutathione is an antioxidant co-factor required for glyoxalase I activity, an enzyme which degrades the AGE precursor methylglyoxyl. Increased production of ROS is also thought to deplete
glutathione levels. Through the reduction of oxidative stress, prebiotics may assist in the maintenance or up-regulation of the glyoxylase pathway.

**Reduction of hyperglycemia**

Both transient and chronic elevations in blood glucose increase endogenous AGE generation. Activation of GPR43 in adipocytes by proprionate inhibits lipolysis and lowers glycemia in healthy individuals [105]. Butyrate has been shown to reverse diet-induced insulin resistance in animal studies [106], possibly by enhancing PPARgamma expression which increases fatty acid oxidation in muscle.

Glucagon-like peptide 1 (GLP-1) is an incretin hormone released from intestinal L-cells in response to consumption of carbohydrates and fats. GLP-1 potentiates glucose-induced insulin secretion, reducing post-prandial blood glucose levels. GLP-1 also enhances satiety and slows gastric emptying. Prebiotic feeding in rats promoted L-cell differentiation in the colon and increased GLP-1 production [107,108], probably through an increase in bacterial production of butyrate.

The consumption of inulin as a dietary supplement may also influence circulating AGE concentrations independently of its prebiotic function. High glycemic index (GI) diets and their resultant hyperglycemic effect have been shown to enhance AGE formation in healthy individuals [109]. Inulin is a soluble fibre which when consumed daily may play a role in the reduction of the GI of the diet. Many soluble fibres are known for their ability to delay gastric emptying and slow the rate of intestinal nutrient absorption, reducing the GI of the carbohydrates in the meal. Regular consumption of prebiotic soluble fibre reduces fasting and post-prandial serum glucose levels in people with impaired glucose tolerance [110] and type 2 diabetes [111].

**Study strengths**

- To our knowledge, this is the first trial to investigate the potential effects of gut bacterial modulation on advanced glycation.
- Random allocation of participants to treatment sequence and intention to treat analysis will ensure study bias is minimised.
- Double-blind crossover placebo-controlled trial.
- Dietary data will be obtained to determine dietary patterns as well as estimates of total energy intake, fat and AGE consumption.
- CML in this study will be measured using a validated ELISA method.
- Dietary AGE consumption will be estimated from an open-source food AGE database, containing AGE values obtained using validated measurement techniques.

**Study limitations**

Type 2 diabetes is a chronic condition which often develops over decades, making it difficult to conduct intervention studies using the presence or absence of diabetes as the primary biological end-point. This study will measure surrogate biochemical markers of early type 2 diabetes pathogenesis, which could be considered a limitation of the trial. Long-term studies will need to be conducted in order to confirm the results of this research.

This study will measure serum CML as an indicator of AGE concentration in blood samples. Multiple other forms of AGEs exist, many of which have not yet been characterised, so the findings of this trial cannot be applied to all members of the AGE family. However, serum CML concentration shows a moderate to high correlation with other known circulating AGEs [39].

**Applicability of research findings**

In Australia, conservative estimates predict that at least 2 million adults will have been diagnosed with type 2 diabetes by 2025 [112]. The burden of disease associated with diabetes has a substantial impact on costs associated directly with health care as well as loss of productivity and decreased quality of life. The widespread consumption of high fat, heat processed foods and the increasing prevalence of obesity in Australia warrant simple interventions including those that prevent AGE-mediated damage. If dietary treatments aimed at altering the gut microbiota prove to be effective strategies for preventing or slowing the development of type 2 diabetes, they could become mainstream therapies for individuals with diabetes risk factors.

**Abbreviations**

AGE: Advanced glycation endproduct; sRAGE: Soluble receptor for advanced glycation endproducts; HOMA: Homeostasis model assessment; TAC: Total antioxidant capacity; TNFa: Tumour necrosis factor alpha; IL-6: Interleukin 6; VCAM-1: Vascular cell adhesion molecule 1; RAGE: Receptor for advanced glycation endproducts; CML: Carboxymethyl-lysine; MG: Methylglyoxal; LPS: Lipo polysaccharide; SCFA: Short chain fatty acid; GPR: G-protein coupled receptor; PPY: Peptide YY; GLP-2: Glucagon-like peptide 2; ACE: Angiotensin converting enzyme; DPP-4: Dipeptidyl peptidase 4; Fiaf: Fasting-induced adipocyte factor; ELISA: Enzyme linked immunosorbent assay; NFκB: Nuclear Factor kappa-B; TLR4: Toll-like receptor 4.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

NJK and MTC designed the study, NJK drafted the manuscript with assistance from MTC, GSS and CMR. All authors read and approved the final manuscript.

**Acknowledgements**

The authors thank Associate Professor Rory Wolfe (SPHPM, Monash University) for advice regarding biostatistical analyses. NJ Kellow is the recipient of a National Health and Medical Research Council (NHMRC) Postgraduate Public Health Scholarship APP1039709. MT Coughlan is supported by an Australian and New Zealand Society of Nephrology Early Career Fellowship.
References
1. Henle T: Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids 2005, 29(4):313–322.
2. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813–820.
3. Falli F, Conradi D, Fanti P, Davalli A, Paez A, Giacconi A, Pereggi C, Muscogori G. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev 2011, 7(3):313–324.
4. Kotani K, Lambardi A: C-reactive protein and reactive oxygen metabolites in subjects with metabolic syndrome. J Int Med Res 2012, 40(3):1074–1081.
5. Thorburn PJ: Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci 2005, 1043:111–117.
6. Avery NC, Bailey AJ: The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Parkh Bioi 2006, 54(7):387–395.
7. Rosca MG, Mustata TG, Griner MT, Ozdenir AM, Kern TS, Savedra LJ, Brownlee M, Monnier VM, Weiss MF. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005, 289(2):F420–F430.
8. Coughlan MT, Thoburn DR, Penfold SA, Laskowski A, Harcourt BE, Souris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM: RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009, 20(4):742–752.
9. Yim MB, Yim HS, Lee C, Kang SQ, Chock PB: Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci 2001, 928:48–53.
10. Schmidt AM, Hori O, Chen JX, Crandall J, Zhang J, Cao R, Yan SD, Brett JL, Stem D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995, 96(3):1395–1403.
11. Morita M, Yano S, Yamaguchi T, Sugimoto T: Advanced glycation end products-induced reactive oxygen species generation is partly through NF-kappa B activation in human aortic endothelial cells. J Diabetes Complications 2013, 27(1):11–15.
12. Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, Mizoguchi M, Imazumi T: Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2012, 30(1):42–48.
13. Tan KC, Shui SW, Wong Y, Tam K: Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev 2011, 27(5):488–492.
14. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H: Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005, 1043:461–466.
15. Fiory F, Lambardi A, Miele C, Giudicelli J, Beguinot F, Van Obberghen E: Methylglyoxal impairs insulin signalling and insulin action on glucose-injected insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia 2011, 54(11):2941–2952.
16. Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas-Bonke V, Webster DE, Miyazaki J, Kay TW, Statter RM, Kaye DM, Drew BG, Kingsley BA, Fourbanos T, Spoon PH, Harrison LC, Kingwell BA: Advanced glycation end products are direct modulators of beta-cell function. Diabetes 2011, 60(10):2523–2532.
17. Birlouez-Aragon I, Sawaедa G, Tessler FJ, Galinner A, Art-Ameerlu L, Lacoste F, Niamba CN, Alt N, Somoza V, Lecerf JM: A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 2010, 91(5):1220–1226.
40. Kilhov BD, JuttiBian A, Letho S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M. Increased serum levels of methyldihydrolipoamide dehydrogenase (LA) and age-associated increases with cardiovascular disease mortality in nondiabetic women. Atherosclerosis 2009, 205(2):590–594.

41. Lapolla A, Pianelli F, Sartori G, Cerelli A, Raggi E, Reitano R, Bacarlin L, Lavender B, Fedele D. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral arterial disease. Diabetes Care 2007, 30(3):670–676.

42. Sembra RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 2009, 57(10):1874–1880.

43. Kolida S, Meyer D, Gibson GR. A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr 2007, 61(10):1189–1195.

44. Causely JE. Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal health in hypercholesterolemic men. Nutr Res 2000, 20(2):191–201.

45. Lecerf JM, Depeint F, Clerc E, Dugent Y, Niamba CH, Rhazi L, Cayzelle A, Abdelnour G, Jaruga A, Younes H, Jacobs H, Lambrey G, Abdelnour AM, Pouillart PR, Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr 2012, 108(10):1857–1858.

46. Hull GLJ, Amers JM, Cuzick GJ. N(Pro)–(carboxymethyl)lysine content of foods commonly consumed in a Western Style diet. Food Chem 2012, 131(7):170–174.

47. Bihunjak DI, Simpson CA, Sullivan RR, Caseria DM, Kerstetter JE, Insgina KL. Dietary protein-induced increases in urinary calcium are accompanied by similar increases in urinary nitrogen and urinary urea: a controlled clinical trial. J Acad Nutr Diet 2013, 113(3):447–451.

48. Craig CL, Marshall AL, Spiston M, Baume AE, Booth ML, Ainsworth BE, Pratt M, Beklund U, Nygren A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003, 35(5):1381–1395.

49. Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kentsch-Engel R, Stahl P. Elevated serum levels of N(equil)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004, 47(8):1376–1379.

50. Zhang X, Frischmann M, Kentsch-Engel R, Steinmann K, Stopper H, Niwa T,また,まな. Two inmunohistochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med 2005, 43(5):503–511.

51. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1988, 28(7):412–419.

52. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monasta T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity; studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23(1):57–63.

53. Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Heiland A, Krajcovic-Kudackova M. Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians. Mol Nutr Food Res 2006, 50(10):858–868.

54. Vassara H, Uniari J, Cai W, Striker G. Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci 2008, 1126:46–52.

55. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga RS, Uniari J, Vassara H. Advanced glycation end products in commonly consumed foods. J Am Diet Assoc 2004, 104(12):1287–1291.

56. Shen Q, Chen YA, Tuohy KM. A comparative in vitro investigation into the effects of cooked meats on the human faecal microbiota. Anaerobe 2010, 16(6):572–577.

57. Connolly ML, Lovegrove JA, Tuohy KM. In vitro fermentation characteristics of whole grain wheat flakes and the effect of toasting on prebiotic potential. J Med Food 2012, 15(1):33–43.

58. de Preter V, Harmer HM, Windley K, Verbeke K. The impact of pre- and/or probiotics on human colonic metabolites: does it affect human health? Mol Nutr Food Res 2011, 55:1465–74.

59. Faist V, Ebendalder HF. Metabolic transit and in vivo effects of melanoïdins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab 2001, 45(1):1–12.

60. Rapin JR, Wiensperger N. Possible links between intestinal permeability and food processing: A potential therapeutic niche for gluten. Clinics (Sao Paulo) 2010, 65(6):635–643.

61. Schopach W. Effects of short-chain fatty acids on gut morphology and function. Gut 1994, 35(Suppl 3):S35–S38.

62. Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J, Jahn HM, Jeong JH. Assessment of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig Dis Sci 2006, 51(4):693–697.

63. Canani RB, Costanzo MD, Leone L, Pedata M, Meil R, Calligano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011, 17(12):1519–1528.

64. Delzenne NM, Cani PD. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr 2011, 31:15–31.

65. Russo F, Linsalata M, Clemente C, Chiloio M, Orlandi A, Marconi E, Chimenti G, Rizzuto G. Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glaucagon-like peptide 2 in healthy young volunteers. Nutr Res 2012, 32(12):940–946.

66. Cani PD, Possemiers S, Van de Wiele T, Guvot Y, Everard A, Rottier O, Gearts L, Naslain D, Neyrick A, Lambert DM, Mucicoll GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2 driven improvement of gut permeability. Gut 2009, 58(8):1091–1103.

67. Cani PD. Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. Clin Microbial Infect 2012, 18(Suppl 4):50–53.

68. Schalkwijk CG, Miyata T. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutic. Amino Acids 2012, 42(4):1193–1204.

69. Anderson MM, Heinecke JW. Production of N(Pro)–(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 2003, 52(8):2137–2143.

70. Huebschmann AG, Regensteiner JG, Vassara H, Reusch JE. Diabetes and advanced glycation end products. Diabetes Care 2006, 29(6):1420–1423.

71. Hildebrandt MA, Hoffmann C, Shermill-Max SA, Kelbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137(5):1716–1724, e1711–e1712.

72. Vrieze A, Hollemann F, Zoetendal EG, de Vis WM, Hoekstra JB, Neusdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010, 53(4):606–613.

73. Esteve E, Ricart W, Fernandez-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiota co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care 2011, 14(6):483–490.

74. Cani PD, Aamar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrick AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpic T, Chamontin B, Ferrieres J, Tant JF, Gibson GR, Castella L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56(7):1761–1772.
80. Priebe MG, Wang H, Weening D, Schepers M, Preston T, Vonk RJ. Factors related to colonic fermentation of nondigestible carbohydrates of a previous evening meal increased tissue glucose uptake and moderate glucose-associated inflammation. Am J Clin Nutr 2010, 91(1):99–97.

81. Creely SJ, McIntern PG, Kusminski CM, Fisher FM, Da Silva NF, Hanoliak M, Evans M, Harte AL, Kornar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292(3):E740–E747.

82. Amar N. Energy intake is associated with endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 2010, 59(9).

83. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR. Satiety effects of a dairy beverage and butyrate in healthy human: a pilot study. Diabetesologia 2007, 50(1):2374–2383.

84. Lin MY, Yen CL. Inhibition of lipid peroxidation by Lactobacillus acidophilus and Bifidobacterium longum. J Agric Food Chem 1999, 47(9):3661–3664.

85. Yen CH, Kuo YW, Tseng YH, Lee MC, Chen HL. Beneficial effects of fructose-oligosaccharides supplementation on fecal bifidobacteria and index of peroxidation status in constipated nursing-home residents—a placebo-controlled, diet-controlled trial. Nutrition 2011, 27(3):323–328.

86. MaslowskI KM, Vieira AT, Ng A, Kranich J, Sierrr F, Yu D, Schilter HC, Rolf MS, Mackay F, Artis D, Xavier RJ, Teixeira MMA, Mackay CR. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461(7268):1282–1286.

87. Vinoso MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Microbes 2011, 11(10):859–876.

88. Lewis K, Lutgendorf F, Phan V, Soderholm JD, Sherman PM, McKay DM. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 2010, 16(7):1138–1148.

89. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007, 86(3):1282–1292.

90. Krogh-Madsen R, Pompaard P, Akstroom T, Muller K, Schmitz O, Pedersen BK. Effect of short-term intraduodenal lipolysis on the immune response during low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab 2008, 294(2):E371–E379.

91. Macia L, Thibout NM, Binge LC, Marino E, Rogers KE, MaslowskI KM, Vieira AT, Kranich J, Mackay CR. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev 2012, 245(1):164–176.

92. MaslowskI KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol 2011, 12(1):5–9.

93. Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 2011, 62:361–380.

94. Guigliucci A, Kotani K, Taing J, Matsuoka Y, Sano Y, Yoshimura M, Egawa K, Horikawa C, Kitagawa Y, Kiso Y, Kimura S, Sakane N. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Nutr Metab 2009, 54(3):197–201.

95. Cani PD, Joly E, Horsmans Y, Delzenne NM. Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 2006, 60(5):567–572.

96. Parmet IA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009, 89(1):1751–1759.

97. Ruijschopt RBA, te Giffel MA. Satiety effects of a dairy beverage fermented with propionic acid bacteria. Int Dairy J 2008, 18(5).

98. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101(16):7378–7373.

99. Aronsson L, Huang Y, Parini P, Korach-Andre M, Hakansson J, Gustafsson JA, Pettersson S, Arulampalam V, Rafter J. Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiotensin-1-14 protein (ANGPTL4). PLos One 2010, 5(10). doi:10.1371/journal.pone.001087.

100. Dewulf EM, Cani PD, Neyrinck AM, Possemiers S, Van Holle A, Muccioli GG, Delvaque L, Binda LB, Pachljan BD, Soeth FM, Migneflet E, Francois M, Larondelle Y, Delzenne NM. Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARgamma-related adipogenesis in the white adipose tissue of high-fat-fed mice. J Nutr Biochem 2011, 22(8):712–722.

101. Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Rep Pract 2012, 2012:82716.